Dr. Jotte on the Low Rate of Screening in Lung Cancer

Robert M. Jotte, MD, PhD
Published: Tuesday, Sep 11, 2018



Robert M. Jotte, MD, PhD, medical director and co-chair of the USON Thoracic Committee at Rocky Mountain Cancer Centers, discusses the low rate of screening for lung cancer.

There are many reasons why there is such a low rate of lung cancer screening, explains Jotte. The primary reason is that the topic is not being brought up. Primary care providers are expected to address a variety of problems in a relatively short office visit, and so lung cancer screening is often overlooked. Physicians must decipher what the immediate risk to the patient is, and proceed accordingly. 

In a 15-minute appointment, a patient is expected to disclose all their problems, have the physician address those problems, and take a couple minutes to discuss a risk that may never materialize. However, for the patients in whom it does materialize, it can be lifesaving, says Jotte.


Robert M. Jotte, MD, PhD, medical director and co-chair of the USON Thoracic Committee at Rocky Mountain Cancer Centers, discusses the low rate of screening for lung cancer.

There are many reasons why there is such a low rate of lung cancer screening, explains Jotte. The primary reason is that the topic is not being brought up. Primary care providers are expected to address a variety of problems in a relatively short office visit, and so lung cancer screening is often overlooked. Physicians must decipher what the immediate risk to the patient is, and proceed accordingly. 

In a 15-minute appointment, a patient is expected to disclose all their problems, have the physician address those problems, and take a couple minutes to discuss a risk that may never materialize. However, for the patients in whom it does materialize, it can be lifesaving, says Jotte.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x